EP1711204A1 - Inducteurs de monopara-immunite a base de myxomavirus attenues du lapin - Google Patents

Inducteurs de monopara-immunite a base de myxomavirus attenues du lapin

Info

Publication number
EP1711204A1
EP1711204A1 EP05701103A EP05701103A EP1711204A1 EP 1711204 A1 EP1711204 A1 EP 1711204A1 EP 05701103 A EP05701103 A EP 05701103A EP 05701103 A EP05701103 A EP 05701103A EP 1711204 A1 EP1711204 A1 EP 1711204A1
Authority
EP
European Patent Office
Prior art keywords
virus
passages
viruses
myxoma
attenuated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05701103A
Other languages
German (de)
English (en)
Inventor
Anton Mayr
Barbara Mayr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Bavarian Nordic AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic AS filed Critical Bavarian Nordic AS
Priority to EP10014101A priority Critical patent/EP2327420A3/fr
Publication of EP1711204A1 publication Critical patent/EP1711204A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Definitions

  • the invention relates to monoparamunity inducers based on paramunizing viruses or virus components, characterized in that the viruses or virus components originate from an attenuated myxomavirus strain of the rabbit, a method for producing the monoparamity inducers and their use as medicaments.
  • the body's immune system of highly developed organisms includes an antigen-specific and an antigen-unspecific part. Both parts of the immune system are networked and interact with each other.
  • the antigen-specific mechanisms are responsible for the build-up of immunity, the antigen-specific ones for the build-up of paramunity.
  • Paramunity refers to the state of a well-regulated and optimally functioning non-specific defense system, combined with a rapidly emerging, time-limited, increased protection against a large number of different pathogens, antigens and other noxious agents.
  • paramunity For historical and functional reasons, the basis for the emergence of paramunity is the so-called primitive, non-selective and conditionally selective, parasitic defense mechanisms that are old from a phylogenetic point of view.
  • the paraspecific activities of the antigen-unspecific immune system include non-selective protective elements, such as foreign material-eating organelles, and limited selective protective elements, such as micro- and macrophages, natural killer cells, dendritic cells and soluble factors such as cytokines, which react pathogen-unspecific or antigen-unspecific depending on their genesis.
  • non-selective protective elements such as foreign material-eating organelles
  • limited selective protective elements such as micro- and macrophages, natural killer cells, dendritic cells and soluble factors such as cytokines, which react pathogen-unspecific or antigen-unspecific depending on their genesis.
  • Paraspecific activities can be observed in the organism concerned immediately after antigen contact, while the effects of the antigen-specific immune system only take days or weeks.
  • the paraspecific immune defense is a physiological process and can be defined as "primary control" when dealing with the environment. It is irreplaceable not only for the lower organisms, but especially for the more highly and highly developed vertebrates. Primary congenital defects in this biological Defense systems lead to life-threatening situations.
  • One example is the "Chediak-Steinbrinck-Higashi syndrome” of humans, which is characterized by granulocyte defects and dysfunctions of the natural killer cells (NK cells) and in most cases until the 10th Leads to the death of the patient.
  • the state of paramunity is characterized by an increased phagocytosis rate, an increased function of spontaneous cell-mediated cytotoxicity (NK cells) and an increased activity of other lymphoreticular cells.
  • certain cytokines are released, which have a stimulating and / or inhibiting effect (for example via repressor mechanisms) both with the cellular elements and with one another.
  • This closely networked and gradually reacting biological system of paramunity with its different acceptor, effector and target cells as well as the signal-transmitting cytokines is also closely connected to the hormone and nervous system. It is an important part of the communication, interaction and regulation network. Paramunity is initiated by paramunization.
  • Paramunization inducers are used for paramunization, to which certain harmlessness and efficacy criteria are set, which distinguish them from immunostimulants.
  • the paramunity inducer per se is not comparable to a repellent, nor to a chemical, an antibiotic, vitamin or hormone. Rather, it activates the paraspecific immune system via a step-by-step mechanism, so that it mobilizes sufficient cellular and humoral defense mechanisms.
  • the paramunity inducer acts both regulating and repairing with regard to the immune defense. With regard to the mode of action of paramunity inducers, it is known that they are taken up by phagocytic cells (acceptor cells), which are thereby activated and release mediators, which in turn mobilize effector cells. These finally switch on the regulatory mechanisms of the parasitic defense.
  • the present invention is based on the paramunizing properties of attenuated myxoma viruses and / or their virus components.
  • Attenuation leads to loss of virulence and contagiosity, a reduction in the immunizing properties and the host spectrum and to minor changes in the pathogen genome with the appearance of deletions, preferably in the terminal areas. At the same time, there is usually an increase in the paramunizing activities of the modified pathogen.
  • Attenuation especially when attempting experimental attenuation through genetic engineering manipulations, can also lead to an increase in virulence and contagiosity.
  • Myxoma viruses are the causative agents of myxomatosis, a cyclical, contagious viral general disease of wild and domestic rabbits, which is characterized by generalized, partially hemorrhagic subcutaneous edema on the head and all over the body, with preference for the anal region, the vulva and the tube, like no other infectious disease is. If myxomatosis is newly introduced into a previously disease-free country, it is rapid and fatal. After the virus becomes sedentary, the epidemic character changes up to clinically unapparent infections (Mayr A .: Medical microbiology, infection and epidemics, 7th edition, Enke-Verlag, Stuttgart, 2002).
  • the disease is widespread among American cottontail rabbits of the genus Sylvilagus, which only colonize the new world. These wild rabbits are the only natural reservoir of the disease. The infection is mild. In contrast, the disease in European wild and domestic rabbits of the genus Oryctolagus, which are also native to Australia, has an almost 100% mortality rate when the pathogen is newly introduced.
  • Myxomavirus (genus Leporipoxvirus) is narrowly limited. In general, the virus only reproduces in American cottontail rabbits and in European domestic and wild rabbits. However, were also isolated Infections in European wild rabbits observed. Attempts to transfer it to other animal species and to humans were negative.
  • the present invention has for its object to provide new monoparamunity inducers for human medicine and veterinary medicine. Another object of the present invention is to provide a method for producing such monoparamity inducers. It is also an object of the present invention to provide pharmaceutical compositions for use as medicaments based on monoparamity inducers.
  • the present invention relates to monoparamunity inducers based on paramunizing viruses or virus components, characterized in that the viruses or virus components originate from an attenuated myxoma virus strain of the rabbit.
  • the virus components preferably comprise paramunizing virus envelopes or aberrant forms of virus envelopes of an attenuated myxoma virus strain.
  • Preferred strains which have the parameterizing properties according to the invention are the strains M-2, M-7, Lausanne, Aust / Uriarra / Verg-86 /.
  • the strains M-7, Lausanne, Aust / Uriarra / Verg-86/1 are also suitable for the production of live vaccines, since their virulence is only partially weakened in order to have a sufficiently immunizing effect.
  • a monoparamity inducer based on the myxomavirus strain M-2 is particularly preferred.
  • An attenuated myxoma virus strain, produced by the method according to the invention described below, is available at the depository of the Public Health Laboratory Service (PHLS), Center for Applied Microbiology & Research, European Collection of Animal Cell Cultures (ECACC), Salisbury, Wiltshire, United Kingdom the deposit number 03121801.
  • PHLS Public Health Laboratory Service
  • ECACC European Collection of Animal Cell Cultures
  • Salisbury, Wiltshire United Kingdom the deposit number 03121801.
  • the invention further relates to a method for producing monoparamunity inducers based on an attenuated myxomavirus strain of the rabbit.
  • myxoma viruses are first isolated from infected tissue of a rabbit typically suffering from generalized myxomatosis. The virus is then adapted to a permissive cell system, ie to a cell material that allows the virus to multiply, such as cell cultures, incubated chicken eggs or experimental animals.
  • a permissive cell system ie to a cell material that allows the virus to multiply, such as cell cultures, incubated chicken eggs or experimental animals.
  • cells from the natural host or a species closely related to the host can be used for adaptation.
  • permissive cell systems for myxoma viruses For example, chicken embryo fibroblasts (FHE) are suitable, as are cell cultures made from rabbit kidneys or testicles.
  • Preferred according to the invention is the adaptation of the isolated myxoma virus to the chorioallantoic membrane (CAM) of incubated chicken eggs over one or more passages, preferably over 2 to 6 passages and particularly preferably over 3 passages.
  • the isolated viruses are vaccinated on the CAM and multiplied by passing through the CAM.
  • the myxoma viruses are preferably first isolated from infected tissue by multiplication in a permissive cell system.
  • a permissive cell system can be inoculated, for example, with infected tissue homogenate obtained by digestion.
  • the viruses obtained by first propagation are either further adapted to the same permissive cell system type that was already used for the isolation, or a different, further permissive cell system is used.
  • the adaptation of the virus to the same permissive cell system type that is also used for the isolation is preferred.
  • Myxoma viruses are thus preferably isolated from infected tissue by multiplication in a permissive cell system and then adapted to the permissive cell system by further passages.
  • a first cultivation or isolation of the myxoma viruses by multiplying chicken eggs incubated on the CAM and subsequent adaptation of the virus on the CAM over further passages, preferably over a further 2 passages.
  • the allantoic liquid of incubated chicken eggs can also be used for the cultivation and / or adaptation.
  • the actual attenuation then takes place through permanent passages on one or more permissive cell cultures until attenuation or the desired degree of attenuation of the virus is achieved.
  • various permissive cell systems can first be tried out to multiply the virus, and then one or more cell systems in which the highest infectivity titers are achieved can be selected for further passages.
  • Both primary and secondary cell cultures as well as permanent or continuous cell lines are suitable for attenuation through long-term passages.
  • attenuation can be achieved by multiplication in primary or secondary chicken embryo fibroblast (FHE) cultures or in cultures of permanent FHE cells.
  • FHE primary or secondary chicken embryo fibroblast
  • the virus is preferably passaged or propagated in a permanent cell culture, in particular a Vero cell culture, for attenuation of the myxoma virus, preferably over 80 to 150 passages and particularly preferably over 120 passages.
  • a permanent cell culture in particular a Vero cell culture
  • the virus is passaged according to the invention on a binary, permanent cell line, AVIVER cells preferably being used. This cell or cell culture was obtained by a cell fusion between chicken embry fibroblasts (FHE) and Vero monkey kidney cells.
  • the isolated and adapted viruses are preferably passaged in a first step in Vero cell cultures, the viruses are subsequently transferred into a binary AVIVER cell culture and in these preferably over 10 to 50 passages, in particular over 20 to 30 passages, and particularly preferably increased over 25 passages.
  • the attenuated myxoma virus can be multiplied by additional attenuation passages.
  • a further multiplication of the viruses takes place preferably via further passage in Vero monkey kidney cells, in particular over 100 to 200 passages.
  • a particularly preferred, further process step is an additional inactivation of the attenuated myxoma virus.
  • Inactivation can take place by chemical treatment, radiation, exposure to heat or pH, in particular by chemical treatment with beta-propiolactone.
  • beta-propiolactone By treating the attenuated myxoma viruses with beta-propiolactone, the paraspecific activities are increased, while the immunizing properties that may still be present after attenuation are lost.
  • a particularly preferred embodiment of the method according to the invention comprises the following steps: isolating myxoma viruses from infected tissue of a rabbit typically suffering from generalized myxomatosis by multiplying chicken eggs incubated on the chorioallantoic membrane (CAM) and subsequently adapting the virus to the CAM over a further 2 passages; - attenuation of the isolated viruses by passage in Vero cell cultures, preferably over 120 passages; Transfer of the viruses into a binary AVIVER cell culture, the AVIVER cells being obtained by a cell fusion between chicken embryo fibroblasts (FHE) and Vero monkey kidney cells, and attenuation of the virus in this cell culture over 10 to 50, preferably 25, passages. subsequent retransfer of the virus to Vero monkey kidney cells and multiplication of the viruses by further attenuation passages in the Vero cells, preferably over approximately 150 passages;
  • Attenuation through permanent passage is usually completed by 3 to 5 final plaque dilutions. After obtaining and testing different clones, those clones are selected for further propagation with which the highest infectivity titer is achieved and with which a high paramunizing effectiveness - e.g. in the VSV challenge test in the baby mouse. This procedure is intended in particular to provide genetically uniform virus material for further use.
  • Attenuation denotes the experimental change of the originally virulent myxoma virus into the modified form, while simultaneously increasing the paramunizing properties. Attenuation can be demonstrated by one or more of the following properties: reduction or Weakening or loss of virulence for European domestic and wild rabbits (genus Oryctolagus caniculus csp.), Weakening or loss of contagiosity, narrowing of the host spectrum in cell cultures, change in the immunizing properties, acquisition of paramunizing, short-term protective activities. Attenuation can lead to deletions in the terminal Area of the myxoma virus genome, and with increasing degree of attenuation an increasing number of deletions in the viral genome is observed.
  • the degree of attenuation can be checked and checked in the course of the passages by appropriate, suitable effectiveness tests, as are known in the prior art (cf., for example, US Pat. No. 6,805,870, column 12, and the further literature references cited therein) and by cloning.
  • the present invention further relates to attenuated myxomaviruses which can be obtained by the process according to the invention, pharmaceutical compositions which comprise the attenuated myxomavirus or the myxomavirus monoparamunity inducer according to the invention, and the use of the myxomavirus monoparamunity inducer for activating the paraspecific immune system in a mammal or Use of the attenuated virus for the manufacture of a corresponding drug.
  • the myxomavirus monoparamunity inducers according to the invention are suitable for the treatment and / or prophylaxis of immune system dysfunctions, immunosuppression, immune deficiency disorders, dysfunctions of homeostasis between hormone, circulatory, metabolic and nervous systems, neonatal infection threats, tumor diseases, Viral diseases, bacterial diseases, therapy-resistant infectious factor diseases, viral and bacterial mixed infections, chronic manifestations of infectious processes, liver diseases of different origins, chronic skin diseases, herpes diseases, chronic hepatitis, flu infections, endotoxin damage.
  • the monoparamity inducers according to the invention are generally harmless to the environment and are effective in terms of paramunization for mammals, e.g. Human, horse, dog, cat, pig, for birds and also for reptiles, such as Lizards, snakes, turtles. They are therefore particularly well suited for use in human and veterinary medicine.
  • the monoparamunity inducers according to the invention have very good paramunizing activity with high potency. They can be produced in a suitable manner using the method according to the invention and are safe for use in the medical field. As a result of the attenuation of the myxoma viruses, the immunizing properties of the myxoma viruses decrease, while the paraspecific activities increase.
  • the monoparamity inducers according to the invention therefore have no immunizing, but rather paramunizing properties, which enables repeated and continuous use. These paramunizing properties of the rabbit myxoma virus or its paramunizing virus components are surprising and were not predictable.
  • paramunization denotes the medicinal activation of the cellular elements of the paraspecific immune system and the associated formation or release of cytokines with the aim of eliminating dysfunctions, the non-pathogen and non-antigen-specific protection of To increase the individual quickly and to act as a regulator between the immune, hormone, nervous and vascular systems: Paramunization leads to the protective state of the paramunity.
  • paramunity denotes the actively acquired state of an optimally regulated and functioning paraspecific defense system, combined with a rapidly emerging, time-limited protection against a large number of pathogens, antigens and other noxious substances.
  • the phagocytosis rate, the function of the NK cells (natural killer cells) and the activity of other lymphoreticular cells (e.g. dendritic cells) are increased to the physiological optimum.
  • paramunity inducer denotes a pyrogen-free, non-toxic medicament which is intended to be used in humans and animals for the production and regulation of the body's own defense and protection mechanisms in the sense of a paramunization.
  • myxomavirus monoparamity inducer refers to a medicament based on rabbit attenuated myxoma viruses or an attenuated myxoma virus strain, including the paramunizing virus components and the components thereof, which are preferred in an organism in a mammal (e.g. human) to produce the state of paramunity.
  • myxomavirus denotes the species of the myxomatosis virus of the genus Leponpoxvirus.
  • the myxomavirus belongs to the subfamily of the Chordopoxviridae and the family of the Poxvi dae (smallpox viruses).
  • paramunizing virus components encompasses a large number of viral structures which are derived from a myxoma virus with paramunizing properties, for example reproductive or inactivated freshly isolated myxoma viruses, reproductive or inactivated recombinant myxoma viruses, which derived from freshly isolated myxoma viruses, Virus envelopes, the separated envelopes, and cleavage products and aberrant forms of these envelopes, individual native or recombinant polypeptides or proteins, in particular membrane and surface receptors, which occur in freshly isolated myxoma viruses or are recombinantly expressed by a genetically modified myxoma virus or part of its genetic information.
  • Tables 1 to 4 summarize the clinical results with the myxoma virus monoparamunity inducer PIND-MYXO based on the attenuated myxomatosis cell culture virus, strain M-2, in humans.
  • Table 1 shows the clinical results in the prophylactic use of the myxomavirus monoparamity inducer PIND-MYXO in humans.
  • Table 2 shows the clinical results in the therapeutic use of the myxoma virus monoparamunity inducer PIND-MYXO in humans.
  • Table 3 shows the effect of paramunization with myxomavirus monoparamunity inducer (PIND-MYXO) in patients with low immune parameters (7 days after PIND-MYXO application)
  • Table 4 shows the effect of paramunization with myxomavirus monoparamunity inducer (PIND-MYXO) in patients with increased immune parameters (7 days after PIND-MYXO application)
  • the invention is based on the surprising finding that attenuated rabbit myxoma viruses or their paramunizing components are able to produce very good paramunizing properties in a recipient organism, which lead to the protective state of the paramunity.
  • the basis for this invention was the first successful attenuation of rabbit myxoma viruses in cell cultures.
  • the monoparamity inducers according to the invention are preferably based on lyophilized, attenuated and inactivated myxoma viruses of the rabbit or their paramunizing virus components.
  • the attenuated myxomaviruses according to the invention or their virus components preferably originate from one myxomavirus strain or from several different attenuated myxomavirus strains. It is preferred that the monoparamity inducer according to the invention combinations of one or more strains of myxoma virus or their paramunizing virus components.
  • the paramunizing properties caused by the application of myxomavirus monoparamunity inducer in a mammal, such as in humans, are particularly useful for eliminating dysfunctions, increasing non-antigen-specific protection of an individual, eliminating stress-related effects, or otherwise (e.g. drug-induced immunosuppression or immunodeficiency and to have a regulatory effect between the immune, hormone and vascular systems.
  • the invention is further based on successful attenuation of a myxomavirus strain by passage over cell cultures, the virulent and / or immunizing properties of the myxomavirus strain being reduced or lost. Additional inactivation of the myxoma viruses can also take place by irradiation, exposure to heat or pH or, particularly preferably, by chemical treatment with beta-propiolactone.
  • the monoparamity inducers are based on attenuated, lyophilized myxoma viruses, and individual virus components of a myxoma virus which are suitable for causing paramunizing activities in an organism are also included in the invention.
  • an embodiment of the manufacturing method according to the invention of the monoparamunity inducer based on an isolated and attenuated myxomavirus strain of the rabbit is to be presented via cell culture passage.
  • the production process is not limited to this preferred strain, but is equally applicable to other rabbit myxomavirus strains.
  • Also included in the present invention are recombinant forms of a myxoma virus strain which have been produced by means of genetic modification.
  • Recombinant myxoma virus strains are preferred in which one or more sections in the genome which code for cytokine receptors have been modified by a modification in the form of an addition, substitution or deletion, the receptor properties of the cytokine receptor being lost as a result of the modification ,
  • These are preferably the gene segments which code for the receptors for interferons (1FN), interleukins (IL) and tumor necrosis factors (TFN), in particular for IFN- ⁇ -R, IFN ⁇ -R, TNF-R, IL-1-R, IL - 2-R, IL-6-R and) L-12-R.
  • the numerical values given here with regard to the incubation period or the number of passengers over cell cultures should not be interpreted as limiting. Minor modifications of these parameters and modifications which are obvious to the person skilled in the art and which also lead to the preparation of attenuated myxoma viruses are equally encompassed by this invention.
  • a preferred embodiment of the present invention relates to the successful attenuation of the myxomavirus strain M-2.
  • the myxoma virus strain M-2 was isolated from European wild rabbits suffering from myxomatosis (Herrlich A., Mayr A. and Münz E .: "Die Pocken", 2nd edition, Georg Thieme Verlag, Stuttgart, 1967)
  • the modified skin cells which have been obtained from the subcutaneous tissue of the sick rabbit, are inoculated with chickens' eggs, preferably incubated for 10-12 days, after disruption to the chorioallantoic membrane (CAM).
  • the myxoma viruses are inoculated over 2 to 6 passages, preferably over three passages.
  • the 2nd to 6th passage serves as the starting material for the further attenuation of the myxoma virus in cell cultures. Attenuation takes place after adaptation of the viruses in the chorioallantoic membrane (recognizable by typical foci on the chorioallantoic membrane) in 3 stages. In stage 1, 80 to 150, preferably 120, continuous so-called final dilution passages are run through in Vero cells (Nero cells, ATCC CCL-81). After going through these passages, the myxoma virus is weakened in its virulence.
  • AVIVER cells are obtained by cell fusion between chicken embryo fibroblasts (FHE) and Vero cells and are called binary permanent cell culture.
  • the last passage via AVIVER cells is transferred back to Vero cells and is continued in the 3rd stage of attenuation for a further 100 to 200 passages, preferably about 157 passages, in Vero cells.
  • the myxoma virus is propagated over a total of more than 300 cell culture passages.
  • the myxomavirus is sufficiently attenuated.
  • a fully synthetic medium is preferably used for culturing the VERO cell cultures and the AVIVER cells, the medium MEM (“minimal essential medium”) plus 5 to 20%, preferably 10% BMS (serum replacement medium) and 5 to 20, is particularly preferred.
  • Virus harvests with a titer of 10 50 to 10 7'5 , preferably of at least 10 6 ' 5 TCID 50 / ml (TCID 50 50% tissue culture infectious dose), are preferably suitable as starting material for the preparation of the monoparamunity inducer PIND-MYXO according to the invention.
  • cpE cytopathic effect
  • MOI multiplicity of infection
  • reticulated cell structures occur for about 3 days and the cells are lysed after about 5 days.
  • the 301st passage in VERO Cells had an infection titer of approximately 10 6.5 TCID 50 / ml.
  • beta-propiolactone is carried out at a concentration of 0.01-1% beta-propiolactone, preferably at a concentration of 0.05% beta-propiolactone. This inactivation leads to a complete loss of any immunizing properties that may still be present, the parasite-specific activities not only being retained but actually increasing significantly.
  • the virus starting material used for virus inactivation should have a virus titer of about 10 50 to 10 70 , preferably at least 10 6 5 TCID 50 / ml.
  • the cleaning is preferably carried out by centrifugation at a low speed (eg 1000 rpm). After centrifugation, 0.5-10% succinylated gelatin (for example polygeline, for example from Hausmann, St. Gallen / Switzerland), preferably 5% succinylated gelatin, is added.
  • the resulting mixture can then be lyophilized in portions of 1.5 ml in appropriate sterile glass vials or ampoules and, if necessary, dissolved with distilled water (distilled water).
  • a volume of 0.5-2 ml, preferably from 1.0 ml of aqua dest. dissolved lyophilisate corresponds to a vaccine dose for humans when administered intramuscularly (see also Mayr A. and Mayr. B .: "From Empiricism to Science", Veterinary Survey, Edition 57: 583-587, 2002).
  • the lyophilized preparation can be stored at temperatures of preferably about + 4 ° C or at lower temperatures, preferably about -60 ° C, stable for an unlimited period.
  • the myxoma virus genome consists of a single linear deoxyribonucleic acid (DNA) with a total length of about 160 kilobases (kB), which codes for several hundred proteins (Herrlich A., Mayr A. and Münz E .: “ Die Pocken ", 2nd ed., Georg Thieme Verlag, Stuttgart, 1967).
  • sequences of the terminally located inverted repeats "(TIR) are approximately 11 kB of the genome section (McFadden, G and Graham, K .: “Modulation of cytokine networks by poxvirus", Virology, Ed. 5: 421-429, 1994).
  • Interferon ⁇ and ⁇ IFN ⁇ , IFN ⁇
  • TNF tumor necrosis factor
  • IL- 1 1, 2, 6 and 12 has come.
  • these cytokines are parasitic defense factors of the non-specific immune system.
  • the cytokines are neutralized by binding to the corresponding virus receptors, so that the virus can multiply uninhibitedly.
  • the deletions of gene segments that code for the cytokine receptors mentioned above mainly affect the terminal regions of the DNA.
  • Attenuated myxoma virus activities The immunizing epitopes and the paraspecific or non-specific epitopes are competing. A decrease in the first-mentioned peptides or proteins therefore leads to an increase in the effect of the paraspecific activities. Residues of immunizing and virulence-increasing proteins are eliminated in the preparation of monoparamity inducers by the method described above for inactivating the attenuated myxoma viruses.
  • the monoparamunity inducer according to the invention is based on the use of attenuated myxoma viruses or their paramunizing components and, due to its paramunizing properties, is suitable for the following prophylactic or therapeutic indications in a patient:
  • paramunity inducers according to the invention can be administered to mammals, including humans, birds and reptiles, parenterally or locally.
  • the local administration of paramunity inducers specifically stimulates the parasitic defense mechanisms in the mucous membranes and in the skin.
  • Parenterally applied paramunizations on the other hand, hardly influence the local defense mechanisms in the skin and mucous membrane, whereby they have a systemic effect.
  • One embodiment of the invention relates to the production of a pharmaceutical composition for local application for the induction of paramunity in the skin and mucous membranes.
  • the pharmaceutical composition preferably relates to a buccal or lozenge tablet based on components of an attenuated and inactivated Myxoma cell culture virus.
  • the Buccal tablets according to the invention are preferably produced with the addition of sorbitol, polyethylene glycol 6.00, potassium hydrogen phosphate, tyrospirol tablet essence, Kollidon 25 and magnesium stearate.
  • PIND-MYXO can also be administered nasally, rectally or vaginally with suitable carriers.
  • the myxomavirus from the edematous subcutis of a European wild rabbit (genus Oryctolagus), which typically has myxomatosis was isolated by incubation on the chorioallantoic membrane (CAM) for 10 days of incubated and broiled egg eggs three times according to the Herrlich et al. adapted to passages on the CAM (Herrlich A., Mayr A. and Münz E .: "Die Pocken", 2nd edition, Georg Thieme Verlag, Stuttgart, 1967).
  • the third CAM passage was opened in a 1st stage VERO cells over 120 passages (ATCC CCL-81, WHO, American Type Culture Collection) adapted, in a second stage multiplied by 24 intermediate passages in AVIVER cell cultures and in the third phase cultivated in VERO cells.
  • a total of about 300 Passages were carried out with the aim of attenuation.
  • the originally virulent myxoma virus was attenuated.
  • the attenuated myxoma virus is propagated in Vero cells.
  • a fully synthetic medium consisting of MEM ("minimal essential medium") plus 10% BMS (serum replacement medium) and 10% lactalbumin hydrolyzate is used for the cultivation of the Vero cell cultures.
  • the lyophilized preparation keeps at room temperatures as well as at temperatures from approximately 4 ° C. to -80 ° C. and is preferably stable indefinitely at approximately 4 ° C. or also approximately -60 ° C.
  • a volume of 1 ml of the in sterile aqua dest. dissolved lyophilisate corresponds to a vaccine dose.
  • the application is deep intramuscular or local (see Examples 3, 4 and 5).
  • the PIND-MYXO inducer according to the invention in dry form is applied locally to the mucous membranes of the upper respiratory tract, preferably nasally, three times a day for prophylaxis or therapy (1 ml per application ) of multifactorial infections (e.g. flu infections).
  • the PIND-MYXO inducer produced in Example 1 in liquid form is rubbed in according to the invention cutaneously for better blood circulation to the skin, for faster healing of wounds and for the treatment of varicose veins or chronic venous insufficiency (leg ulcers) in humans.
  • the lyophilisate can be taken up, for example, in fat cream (eg Bepanthen, linola fat), whereby the pH should be slightly alkaline.
  • This preparation should be freshly made for every application. The application is carried out several times a day by manually rubbing the undamaged skin. Open wounds can be treated by dripping the freshly loosened preparation onto the wound areas. Treatment should be done daily until healing.
  • the monoparamunity inducer PIND-MYXO prepared as in Example 1, is administered parenterally one day before and at the same time as a vaccination with classic, specific vaccines in order to avoid side reactions and to improve the vaccination success.
  • the monoparamunity inducer PIND-MYXO produced as in Example 1, is processed into buccal or lozenges.
  • the production and use of the lozenges for the local paramunization of the ear, nose and throat and oral mucosa is new and part of the invention.
  • the activated oral mucous membranes not only cause a "homing" effect (migration of immune cells into mucous membranes of other organ systems), but also partial parenteral paramunization.
  • the following manufacturing process has proven itself for the production of buccal or lozenges:
  • 5% Kollidon 25 polyvinylpyrrolidone
  • Urea, sorbitol, polyethylene glycol 6000 and magnesium stearate are required to produce the finished tablet.
  • a recipe for a tablet weighing 500.5 mg the following is recommended:
  • the patient should take 4-6 tablets per day at regular intervals to achieve optimal paramunization.
  • the tablets slowly dissolve in the patient's mouth and can be swallowed after dissolution.
  • Table 1 Clinical results with a monoparamunity inducer from attenuated Myxoma cell culture virus in humans - prophylactic applications - (lyophilized inducer 1 OP (1 ml) intramuscularly)
  • Table 2 Clinical results with a monoparamunity inducer from attenuated Myxoma cell culture virus in humans - therapeutic use - (lyphilized inducer 1 OP (1 ml) intramuscularly)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)

Abstract

L'invention concerne des inducteurs de monopara-immunité à base de virus ou de composants de virus para-immunisants obtenus à partir d'une souche de myxomavirus de lapins présentant des affections typiquement généralisées. L'invention concerne également un procédé pour la production de ces inducteurs et leur utilisation sous forme de produits pharmaceutiques servant à optimiser, par régulation, les activités para-immunisantes, pour la prophylaxie et la thérapie de divers dysfonctionnements chez l'homme et l'animal.
EP05701103A 2004-01-23 2005-01-21 Inducteurs de monopara-immunite a base de myxomavirus attenues du lapin Withdrawn EP1711204A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10014101A EP2327420A3 (fr) 2004-01-23 2005-01-21 Inducteurs de monopara-immunite a base de myxomavirus attenues du lapin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004003572A DE102004003572A1 (de) 2004-01-23 2004-01-23 Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
PCT/EP2005/000582 WO2005070453A1 (fr) 2004-01-23 2005-01-21 Inducteurs de monopara-immunite a base de myxomavirus attenues du lapin

Publications (1)

Publication Number Publication Date
EP1711204A1 true EP1711204A1 (fr) 2006-10-18

Family

ID=34800965

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10014101A Withdrawn EP2327420A3 (fr) 2004-01-23 2005-01-21 Inducteurs de monopara-immunite a base de myxomavirus attenues du lapin
EP05701103A Withdrawn EP1711204A1 (fr) 2004-01-23 2005-01-21 Inducteurs de monopara-immunite a base de myxomavirus attenues du lapin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP10014101A Withdrawn EP2327420A3 (fr) 2004-01-23 2005-01-21 Inducteurs de monopara-immunite a base de myxomavirus attenues du lapin

Country Status (16)

Country Link
US (9) US7494799B2 (fr)
EP (2) EP2327420A3 (fr)
JP (1) JP4846598B2 (fr)
KR (2) KR20120076396A (fr)
CN (1) CN1909923B (fr)
AU (1) AU2005205912B2 (fr)
BR (1) BRPI0506489A (fr)
CA (1) CA2547757A1 (fr)
DE (1) DE102004003572A1 (fr)
EA (1) EA009937B1 (fr)
HK (1) HK1095746A1 (fr)
IL (1) IL176634A (fr)
NO (1) NO20063605L (fr)
NZ (1) NZ548189A (fr)
UA (1) UA91501C2 (fr)
WO (1) WO2005070453A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
DE102005027956B4 (de) * 2005-06-16 2009-10-22 Mayr, Anton, Prof. Dr. Dr. h.c. mult. Hochattenuierte Poxvirusstämme, Verfahren zu ihrer Herstellung und deren Verwendung als Paramunitätsinducer oder zur Herstellung von Vektor-Vakzinen
CN102230035B (zh) * 2011-07-06 2013-02-13 中华人民共和国江苏出入境检验检疫局 兔粘液瘤病毒pcr检测试剂盒及其应用
JP6370082B2 (ja) * 2014-04-07 2018-08-08 キヤノン株式会社 情報処理装置、情報処理方法、及びプログラム
JP2017083973A (ja) * 2015-10-23 2017-05-18 富士通株式会社 表示端末装置、表示制御方法および表示制御プログラム

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
GB8426152D0 (en) * 1984-10-16 1984-11-21 Reckitt & Colmann Prod Ltd Medicinal compositions
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2153284B1 (es) 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
MXPA02008873A (es) * 2000-03-14 2003-02-10 Anton Mayr Cepa alterada del virus de vaccinia ankara modificado (mva).
ATE350056T1 (de) * 2000-04-03 2007-01-15 Univ Pittsburgh Zusammensetzungen, die kälteangepasste pferdeinfluenzaviren enthaltende, für die behandlung von bestehende virusinfektionen des atmungssystems
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
AU2003259358A1 (en) * 2002-08-30 2004-03-19 Claire Ashman Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
AU2003297155B2 (en) * 2002-12-16 2010-03-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant vaccine viruses expressing IL-15 and methods of using the same
US6960345B2 (en) * 2003-03-06 2005-11-01 Incell Corporation, Llc Oral vaccinia formulation
AU2004216928B2 (en) * 2003-03-07 2007-03-08 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
DE102005027956B4 (de) * 2005-06-16 2009-10-22 Mayr, Anton, Prof. Dr. Dr. h.c. mult. Hochattenuierte Poxvirusstämme, Verfahren zu ihrer Herstellung und deren Verwendung als Paramunitätsinducer oder zur Herstellung von Vektor-Vakzinen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005070453A1 *

Also Published As

Publication number Publication date
EP2327420A3 (fr) 2011-07-06
US20080267920A1 (en) 2008-10-30
US20120009217A1 (en) 2012-01-12
AU2005205912B2 (en) 2010-07-29
CA2547757A1 (fr) 2005-08-04
US8034356B2 (en) 2011-10-11
KR101209141B1 (ko) 2012-12-06
UA91501C2 (ru) 2010-08-10
US7691391B2 (en) 2010-04-06
WO2005070453A8 (fr) 2006-08-03
US20080213307A1 (en) 2008-09-04
EA200601361A1 (ru) 2006-12-29
EA009937B1 (ru) 2008-04-28
JP2007534664A (ja) 2007-11-29
DE102004003572A1 (de) 2005-08-18
US20110014234A1 (en) 2011-01-20
NO20063605L (no) 2006-08-09
US7494799B2 (en) 2009-02-24
CN1909923B (zh) 2012-10-03
US20100316671A1 (en) 2010-12-16
HK1095746A1 (en) 2007-05-18
US8039004B2 (en) 2011-10-18
AU2005205912A1 (en) 2005-08-04
IL176634A (en) 2011-03-31
US7939085B2 (en) 2011-05-10
CN1909923A (zh) 2007-02-07
JP4846598B2 (ja) 2011-12-28
EP2327420A2 (fr) 2011-06-01
US8142796B2 (en) 2012-03-27
US20120009654A1 (en) 2012-01-12
US20070154455A1 (en) 2007-07-05
KR20060129221A (ko) 2006-12-15
BRPI0506489A (pt) 2007-02-13
KR20120076396A (ko) 2012-07-09
IL176634A0 (en) 2006-10-31
NZ548189A (en) 2009-02-28
US20110020908A1 (en) 2011-01-27
WO2005070453A1 (fr) 2005-08-04
US20120070464A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
DE60314823T3 (de) Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene
DE60113512T2 (de) Veränderter stamm des modifizierten vaccinia-virus ankara (mva)
Baer et al. A model in mice for the pathogenesis and treatment of rabies
Sikes et al. Effective protection of monkeys against death from street virus by post-exposure administration of tissue-culture rabies vaccine
DE69432790T2 (de) Auf papillomaviren basierende pharmazeutische präparate
KR20090053967A (ko) 웨스트 나일 백신
WO2005070453A1 (fr) Inducteurs de monopara-immunite a base de myxomavirus attenues du lapin
JP2007534664A5 (fr)
DE102005027956B4 (de) Hochattenuierte Poxvirusstämme, Verfahren zu ihrer Herstellung und deren Verwendung als Paramunitätsinducer oder zur Herstellung von Vektor-Vakzinen
EP0271447B1 (fr) Mesures préventives pour empêcher la "maladie complexe respiratoire des bovins" par administration d'interféron
Kielstein Systematic control of dermatophytosis profunda of cattle in the former GDR
RU2678981C2 (ru) Композиция от бешенства, содержащая адъювант pika
Vandeputte et al. Glycoprotein vaccine against IBR: effect of vaccination on latency (recrudescence after challenge exposure)
MXPA06008005A (en) Monoparaimmunity inducers based on attenuated rabbit myxoma viruses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060823

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

17Q First examination report despatched

Effective date: 20081120

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130619